Anavex Life Sciences submits compliance plan to Nasdaq after 10-Q delay

Anavex Life Sciences submitted a Compliance Plan to Nasdaq to address a late Form 10-Q filing and seek reinstatement of listing compliance.Key Highlights:Original SEC Filing: ANAVEX LIFE SCIENCES CORP. [ AVXL ] - 8-K - Jul. 20, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…

Anavex Life Sciences submitted a Compliance Plan to Nasdaq to address a late Form 10-Q filing and seek reinstatement of listing compliance.

Key Highlights:

Filed a Compliance Plan with Nasdaq Listing Qualifications to regain compliance with Rule 5250(c)(1).
Deficiency notice issued May 20, 2026 for failure to timely file the 10-Q for quarter ended March 31, 2026.
Notice does not affect current listing or trading on Nasdaq Global Select Market under AVXL.
If plan accepted, Nasdaq may grant extension; if rejected, Company can request a hearing before a Hearings Panel.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.